Literature DB >> 12387744

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2.

Nobuhiko Kayagaki1, Minhong Yan, Dhaya Seshasayee, Hua Wang, Wyne Lee, Dorothy M French, Iqbal S Grewal, Andrea G Cochran, Nathaniel C Gordon, JianPing Yin, Melissa A Starovasnik, Vishva M Dixit.   

Abstract

The TNF-like ligand BAFF/BLyS is a potent survival factor for B cells. It binds three receptors: TACI, BCMA, and BR3. We show that BR3 signaling promotes processing of the transcription factor NF-kappaB2/p100 to p52. NF-kappaB2/p100 cleavage was abrogated in B cells from A/WySnJ mice possessing a mutant BR3 gene, but not in TACI or BCMA null B cells. Furthermore, wild-type mice injected with BAFF-neutralizing BR3-Fc protein showed reduced basal NF-kappaB2 activation. BR3-Fc treatment of NZB/WF1 mice, which develop a fatal lupus-like syndrome, inhibited NF-kappaB2 processing and attenuated the disease process. Since inhibiting the BR3-BAFF interaction has therapeutic ramifications, the ligand binding interface of BR3 was investigated and found to reside within a 26 residue core domain. When stabilized within a structured beta-hairpin peptide, six of these residues were sufficient to confer binding to BAFF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12387744     DOI: 10.1016/s1074-7613(02)00425-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  136 in total

1.  Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype.

Authors:  Hye Sun Kuehn; Julie E Niemela; Karthik Sreedhara; Jennifer L Stoddard; Jennifer Grossman; Christian A Wysocki; M Teresa de la Morena; Mary Garofalo; Jingga Inlora; Michael P Snyder; David B Lewis; Constantine A Stratakis; Thomas A Fleisher; Sergio D Rosenzweig
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

Review 2.  B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors:  Robert H Carter
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 3.  B cell signalling as therapeutic target.

Authors:  R H Carter
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 4.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

5.  Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; Shunhua Guo; Laurence Morel
Journal:  Arthritis Rheum       Date:  2010-08

6.  NF-kappaB2 is required for the control of autoimmunity by regulating the development of medullary thymic epithelial cells.

Authors:  Baochun Zhang; Zhe Wang; Jane Ding; Pärt Peterson; William T Gunning; Han-Fei Ding
Journal:  J Biol Chem       Date:  2006-10-17       Impact factor: 5.157

7.  Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice.

Authors:  Zhong L Ju; Gui Y Shi; Jin X Zuo; Jing W Zhang
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

8.  The role of nuclear factor-kappaB essential modulator (NEMO) in B cell development and survival.

Authors:  Shinyop Kim; Ross N A La Motte-Mohs; Dorothea Rudolph; Juan Carlos Zuniga-Pflucker; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 9.  Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.

Authors:  Noam Jacob; William Stohl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; William J Quinn; Michael P Cancro; Huaxin Gao; Chaim Putterman; Xiaoni Gao; Luminita Pricop; Michael N Koss
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.